Evidence Hub

Management of Gastroesophageal Reflux Disease After Switching to Dexlansoprazole From A Different Proton Pump Inhibitor

Michael Lee Ganz, Kelly Lamothe, Reema Mody, Faisal Riaz, Ahmed Hasan

The American Journal of Gastroenterology, 2012

142 participants

Abstract

Purpose: To assess management of gastroesophageal reflux disease (GERD) (occurrence of breakthrough GERD symptoms, use of rescue medications, and treatment satisfaction) among patients who switched to dexlansoprazole (DEX) from a different PPI. Methods: Patients diagnosed with GERD and their treating physicians participated in a survey conducted from February-September 2011. Patients at least 18 years of age who saw a health care provider at their physician's office at least once in the past 12 months (mos), and used DEX between 2 and 12 mos were eligible for inclusion in the study. In addition to demographic and clinical characteristics, the patient survey also gathered information regarding current and past PPI use, GERD symptoms, use of rescue medications, and treatment satisfaction (7-point Likert scale ranging from completely dissatisfied to completely satisfied) before and after switching to DEX. Physicians provided information on diagnoses and health care resource use during 12 mos prior to the visit when the survey was completed. McNemar and paired-sample t-tests were used to assess unadjusted associations. Logistic regressions were used to adjust for presence of erosive esophagitis, Barrett's esophagus, body-mass index, duration of DEX therapy, experiences with prior PPI, rescue medication use, and use of services. Results: The study included 142 patients, 96 of whom switched to DEX from a prior prescription PPI or from continuous over-the-counter (OTC) PPI. While…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free